AI Insight
Two new studies from Weill Cornell Medicine have revealed that metabotropic glutamate receptors interact with their regulatory proteins in unexpectedly diverse ways. These receptors are considered important but challenging drug targets for neurological conditions. The variable interaction patterns may explain why previous drug development efforts targeting these receptors have failed.
Why it matters
Understanding these hidden receptor-protein interactions could enable more effective drug design for treating brain disorders including epilepsy, depression, and anxiety disorders. This knowledge may help researchers avoid past mistakes in drug development and create more successful therapeutic interventions.
Understand the Science
Metabotropic glutamate receptors, which are important but difficult drug targets, interact in surprisingly varied ways with their principal regulatory proteins, according to two new studies led by Weill Cornell Medicine investigators. The findings represent a major step forward in understanding these receptors and how they can be targeted effectively to potentially treat conditions such as epilepsy, depression and anxiety disorders.
Source: Hidden receptor interactions may explain past failures of brain disorder drugs